-
Je něco špatně v tomto záznamu ?
Distinct phenotypes and 'bystander' effects of senescent tumour cells induced by docetaxel or immunomodulatory cytokines
O. Sapega, R. Mikyšková, J. Bieblová, B. Mrázková, Z. Hodný, M. Reiniš,
Jazyk angličtina Země Řecko
Typ dokumentu časopisecké články
NLK
Free Medical Journals
od 2006 do Před 1 rokem
ProQuest Central
od 2012-01-01
Medline Complete (EBSCOhost)
od 2014-06-01
Nursing & Allied Health Database (ProQuest)
od 2012-01-01
Health & Medicine (ProQuest)
od 2012-01-01
PubMed
30226595
DOI
10.3892/ijo.2018.4553
Knihovny.cz E-zdroje
- MeSH
- bystander efekt účinky léků imunologie MeSH
- docetaxel farmakologie terapeutické užití MeSH
- fenotyp MeSH
- interferon gama imunologie metabolismus MeSH
- lidé MeSH
- modely nemocí na zvířatech MeSH
- myši inbrední C57BL MeSH
- myši MeSH
- nádorové buněčné linie MeSH
- nádory farmakoterapie imunologie patologie MeSH
- proliferace buněk účinky léků MeSH
- protinádorové látky farmakologie terapeutické užití MeSH
- stárnutí buněk účinky léků imunologie MeSH
- TNF-alfa imunologie metabolismus MeSH
- zvířata MeSH
- Check Tag
- lidé MeSH
- mužské pohlaví MeSH
- myši MeSH
- zvířata MeSH
- Publikační typ
- časopisecké články MeSH
Cellular senescence is the process of the permanent proliferative arrest of cells in response to various inducers. It is accompanied by typical morphological changes, in addition to the secretion of bioactive molecules, including proinflammatory cytokines and chemokines [known as the senescence-associated secretory phenotype (SASP)]. Thus, senescent cells may affect their local environment and induce a so-called 'bystander' senescence through the state of SASP. The phenotypes of senescent cells are determined by the type of agent inducing cellular stress and the cell lineages. To characterise the phenotypes of senescent cancer cells, two murine cell lines were employed in the present study: TC-1 and B16F10 (B16) cells. Two distinct senescence inductors were used: Chemotherapeutic agent docetaxel (DTX) and a combination of immunomodulatory cytokines, including interferon γ (IFNγ) and tumour necrosis factor α (TNFα). It was demonstrated that DTX induced senescence in TC-1 and B16 tumour cell lines, which was demonstrated by growth arrest, positive β-galactosidase staining, increased p21Waf1 (p21) expression and the typical SASP capable of inducing a 'bystander' senescence. By contrast, treatment with a combination of T helper cell 1 cytokines, IFNγ and TNFα, induced proliferation arrest only in B16 cells. Despite the presence of certain characteristic features resembling senescent cells (proliferation arrest, morphological changes and increased p21 expression), these cells were able to form tumours in vivo and started to proliferate upon cytokine withdrawal. In addition, B16 cells were not able to induce a 'bystander' senescence. In summary, the present study described cell line- and treatment-associated differences in the phenotypes of senescent cells that may be relevant in optimization of cancer chemo- and immunotherapy.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc19012370
- 003
- CZ-PrNML
- 005
- 20190412101635.0
- 007
- ta
- 008
- 190405s2018 gr f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.3892/ijo.2018.4553 $2 doi
- 035 __
- $a (PubMed)30226595
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a gr
- 100 1_
- $a Sapega, Olena $u Laboratory of Immunological and Tumour Models, Institute of Molecular Genetics of the Czech Academy of Sciences, v.v.i., Prague 4 142 20, Czech Republic.
- 245 10
- $a Distinct phenotypes and 'bystander' effects of senescent tumour cells induced by docetaxel or immunomodulatory cytokines / $c O. Sapega, R. Mikyšková, J. Bieblová, B. Mrázková, Z. Hodný, M. Reiniš,
- 520 9_
- $a Cellular senescence is the process of the permanent proliferative arrest of cells in response to various inducers. It is accompanied by typical morphological changes, in addition to the secretion of bioactive molecules, including proinflammatory cytokines and chemokines [known as the senescence-associated secretory phenotype (SASP)]. Thus, senescent cells may affect their local environment and induce a so-called 'bystander' senescence through the state of SASP. The phenotypes of senescent cells are determined by the type of agent inducing cellular stress and the cell lineages. To characterise the phenotypes of senescent cancer cells, two murine cell lines were employed in the present study: TC-1 and B16F10 (B16) cells. Two distinct senescence inductors were used: Chemotherapeutic agent docetaxel (DTX) and a combination of immunomodulatory cytokines, including interferon γ (IFNγ) and tumour necrosis factor α (TNFα). It was demonstrated that DTX induced senescence in TC-1 and B16 tumour cell lines, which was demonstrated by growth arrest, positive β-galactosidase staining, increased p21Waf1 (p21) expression and the typical SASP capable of inducing a 'bystander' senescence. By contrast, treatment with a combination of T helper cell 1 cytokines, IFNγ and TNFα, induced proliferation arrest only in B16 cells. Despite the presence of certain characteristic features resembling senescent cells (proliferation arrest, morphological changes and increased p21 expression), these cells were able to form tumours in vivo and started to proliferate upon cytokine withdrawal. In addition, B16 cells were not able to induce a 'bystander' senescence. In summary, the present study described cell line- and treatment-associated differences in the phenotypes of senescent cells that may be relevant in optimization of cancer chemo- and immunotherapy.
- 650 _2
- $a zvířata $7 D000818
- 650 _2
- $a protinádorové látky $x farmakologie $x terapeutické užití $7 D000970
- 650 _2
- $a bystander efekt $x účinky léků $x imunologie $7 D024201
- 650 _2
- $a nádorové buněčné linie $7 D045744
- 650 _2
- $a proliferace buněk $x účinky léků $7 D049109
- 650 _2
- $a stárnutí buněk $x účinky léků $x imunologie $7 D016922
- 650 _2
- $a modely nemocí na zvířatech $7 D004195
- 650 _2
- $a docetaxel $x farmakologie $x terapeutické užití $7 D000077143
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a interferon gama $x imunologie $x metabolismus $7 D007371
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a myši $7 D051379
- 650 _2
- $a myši inbrední C57BL $7 D008810
- 650 _2
- $a nádory $x farmakoterapie $x imunologie $x patologie $7 D009369
- 650 _2
- $a fenotyp $7 D010641
- 650 _2
- $a TNF-alfa $x imunologie $x metabolismus $7 D014409
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Mikyšková, Romana $u Laboratory of Immunological and Tumour Models, Institute of Molecular Genetics of the Czech Academy of Sciences, v.v.i., Prague 4 142 20, Czech Republic.
- 700 1_
- $a Bieblová, Jana $u Czech Centre for Phenogenomics, Institute of Molecular Genetics of the Czech Academy of Sciences, v.v.i., Prague 4 142 20, Czech Republic.
- 700 1_
- $a Mrázková, Blanka $u Laboratory of Genome Integrity, Institute of Molecular Genetics of the Czech Academy of Sciences, v.v.i., Prague 4 142 20, Czech Republic.
- 700 1_
- $a Hodný, Zdeněk $u Laboratory of Genome Integrity, Institute of Molecular Genetics of the Czech Academy of Sciences, v.v.i., Prague 4 142 20, Czech Republic.
- 700 1_
- $a Reiniš, Milan $u Laboratory of Immunological and Tumour Models, Institute of Molecular Genetics of the Czech Academy of Sciences, v.v.i., Prague 4 142 20, Czech Republic.
- 773 0_
- $w MED00002350 $t International journal of oncology $x 1791-2423 $g Roč. 53, č. 5 (2018), s. 1997-2009
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/30226595 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20190405 $b ABA008
- 991 __
- $a 20190412101653 $b ABA008
- 999 __
- $a ok $b bmc $g 1391680 $s 1050675
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2018 $b 53 $c 5 $d 1997-2009 $e 20180905 $i 1791-2423 $m International journal of oncology $n Int J Oncol $x MED00002350
- LZP __
- $a Pubmed-20190405